Asthma and chronic obstructive pulmonary disease (COPD) are common inflammatory airway diseases characterized by airway narrowing and increasing global prevalence. Cytokines play a central role in orchestrating chronic inflammation and structural changes in both diseases, making them key targets for new therapies. Asthma is marked by Th2-driven inflammation involving eosinophils, mast cells, and T cells, while COPD is characterized by Th1 and Tc1 cell involvement, neutrophilic inflammation, and fibrosis. Despite similarities in clinical features, the underlying inflammatory patterns differ significantly. Cytokines are classified into lymphokines, proinflammatory cytokines, growth factors, chemokines, and antiinflammatory cytokines. Th2 cytokines like IL-4, IL-5, IL-9, and IL-13 drive asthma, while Th1 and Tc1 cytokines, including IFN-γ, are more prominent in COPD. IL-13 induces airway hyperresponsiveness, mucus hypersecretion, and structural changes, while IL-5 is critical for eosinophil survival and inflammation. Th17 cytokines, such as IL-17A and IL-21, are involved in neutrophilic inflammation in severe asthma and COPD. Proinflammatory cytokines like TNF-α, IL-1β, and IL-6 amplify inflammation in both diseases. Growth factors, including GM-CSF, SCF, TGF-β, and EGF, contribute to airway remodeling. Chemokines recruit inflammatory cells, with CCL2, CCL11, and CCL17 playing key roles in asthma and COPD. Antiinflammatory cytokines, such as IL-10 and TGF-β, have potential therapeutic roles but are limited by their profibrotic effects. Despite efforts to block specific cytokines with antibodies, clinical outcomes have been limited due to cytokine redundancy. Corticosteroids remain the most effective treatment for asthma but are less effective in COPD. New therapeutic strategies targeting upstream cytokines, such as TSLP and IL-13, or broader anti-inflammatory pathways, including NF-κB and p38 MAPK, are being explored. While corticosteroids provide broad anti-inflammatory effects in mild asthma, alternative approaches are needed for severe cases. Overall, understanding cytokine networks is crucial for developing effective treatments for asthma and COPD.Asthma and chronic obstructive pulmonary disease (COPD) are common inflammatory airway diseases characterized by airway narrowing and increasing global prevalence. Cytokines play a central role in orchestrating chronic inflammation and structural changes in both diseases, making them key targets for new therapies. Asthma is marked by Th2-driven inflammation involving eosinophils, mast cells, and T cells, while COPD is characterized by Th1 and Tc1 cell involvement, neutrophilic inflammation, and fibrosis. Despite similarities in clinical features, the underlying inflammatory patterns differ significantly. Cytokines are classified into lymphokines, proinflammatory cytokines, growth factors, chemokines, and antiinflammatory cytokines. Th2 cytokines like IL-4, IL-5, IL-9, and IL-13 drive asthma, while Th1 and Tc1 cytokines, including IFN-γ, are more prominent in COPD. IL-13 induces airway hyperresponsiveness, mucus hypersecretion, and structural changes, while IL-5 is critical for eosinophil survival and inflammation. Th17 cytokines, such as IL-17A and IL-21, are involved in neutrophilic inflammation in severe asthma and COPD. Proinflammatory cytokines like TNF-α, IL-1β, and IL-6 amplify inflammation in both diseases. Growth factors, including GM-CSF, SCF, TGF-β, and EGF, contribute to airway remodeling. Chemokines recruit inflammatory cells, with CCL2, CCL11, and CCL17 playing key roles in asthma and COPD. Antiinflammatory cytokines, such as IL-10 and TGF-β, have potential therapeutic roles but are limited by their profibrotic effects. Despite efforts to block specific cytokines with antibodies, clinical outcomes have been limited due to cytokine redundancy. Corticosteroids remain the most effective treatment for asthma but are less effective in COPD. New therapeutic strategies targeting upstream cytokines, such as TSLP and IL-13, or broader anti-inflammatory pathways, including NF-κB and p38 MAPK, are being explored. While corticosteroids provide broad anti-inflammatory effects in mild asthma, alternative approaches are needed for severe cases. Overall, understanding cytokine networks is crucial for developing effective treatments for asthma and COPD.